Condition
Glomerulonephritis clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Glomerulonephritis clinical trials that are recruiting, at sites in 13 countries (most in Argentina (1), Australia (1), Canada (1)). By phase: Phase 2 (3), Phase 3 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 13Countries
Newest Glomerulonephritis clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Effect of Daratumumab on Kidney Diseases Related to Monoclonal Gammopathy | Phase 2 | Helsinki | Recruiting | Mar 21, 2025 |
| Long-term zigakibart treatment for adults with IgA nephropathy | Phase 3 | Denver, Colorado and 25 other locations | Recruiting | Mar 5, 2025 |
| KP104 for IgA Nephropathy and C3G | Phase 2 | Beijing | Recruiting | Aug 26, 2022 |
| Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant | Phase 2 | Cambridge, England and 5 other locations | Recruiting | Dec 10, 2020 |
| Personalized therapy for patients with IgA nephropathy | Phase 4 | Bari, BA and 1 other locations | Recruiting | Dec 10, 2020 |
All recruiting trials (5)
-
Effect of Daratumumab on Kidney Diseases Related to Monoclonal Gammopathy
This study is testing whether daratumumab can help improve kidney function and overall health in people with kidney diseases linked to monoclonal gammopathy.
-
Long-term zigakibart treatment for adults with IgA nephropathy
Adults with IgA nephropathy who finished an earlier zigakibart trial will receive ongoing subcutaneous zigakibart every two weeks to see if it stays safe and helps over the long term.
-
KP104 for IgA Nephropathy and C3G
This study tests KP104 to see if it helps people with IgA nephropathy and a related kidney condition called C3G.
-
Sparsentan for IgA Nephropathy: safety and activity in adults with incident IgAN and recurrent IgAN after transplant
This trial tests whether sparsentan can be safely given and help kidney outcomes in adults with immunoglobulin A nephropathy, including people newly diagnosed who haven’t had ACEI/ARB therapy and people with recurrent IgAN after kidney transplant.
-
Personalized therapy for patients with IgA nephropathy
This study is testing if personalized treatment plans can help people with IgA nephropathy feel better and lower their chances of serious kidney problems.
Related topics
Quick answers
How many Glomerulonephritis clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 13 countries. The most sites are in Argentina (1 trial), Australia (1 trial), Canada (1 trial), Malaysia (1 trial), Mexico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 3: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.